X0306 4 2018-12-21 1 0001235007 ENDOCYTE INC ECYT 0001241647 KOZIN MARC D 3000 KENT AVE., SUITE A1-100 WEST LAFAYETTE IN 47906 1 0 0 0 Common Stock 2018-12-21 4 D 0 7800 24.00 D 0 D Common Stock 2018-12-21 4 D 0 3300 24.00 D 0 D Stock Option (right to buy) 7.71 2018-12-21 4 D 0 20000 16.29 D 2022-07-25 Common Stock 20000 0 D Stock Option (right to buy) 12.94 2018-12-21 4 D 0 14000 11.06 D 2023-06-19 Common Stock 14000 0 D Stock Option (right to buy) 6.69 2018-12-21 4 D 0 14000 17.31 D 2024-05-15 Common Stock 14000 0 D Stock Option (right to buy) 6.02 2018-12-21 4 D 0 13500 17.98 D 2025-05-14 Common Stock 13500 0 D Stock Option (right to buy) 3.35 2018-12-21 4 D 0 13500 20.65 D 2026-05-05 Common Stock 13500 0 D Stock Option (right to buy) 2.27 2018-12-21 4 D 0 19500 21.73 D 2027-05-04 Common Stock 19500 0 D Stock Option (right to buy) 10.81 2018-12-21 4 D 0 19500 13.19 D 2028-05-03 Common Stock 19500 0 D Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. This restricted stock unit ("RSU") award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. /s/ Michael A. Sherman, Attorney-in-Fact for Marc D. Kozin (power of attorney previously filed) 2018-12-21